These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 22285275)

  • 41. New and emerging treatments for symptomatic tardive dyskinesia.
    Rana AQ; Chaudry ZM; Blanchet PJ
    Drug Des Devel Ther; 2013; 7():1329-40. PubMed ID: 24235816
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of neurolept-induced tardive dyskinesia.
    Jankelowitz SK
    Neuropsychiatr Dis Treat; 2013; 9():1371-80. PubMed ID: 24072972
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An update on tardive dyskinesia: from phenomenology to treatment.
    Waln O; Jankovic J
    Tremor Other Hyperkinet Mov (N Y); 2013; 3():. PubMed ID: 23858394
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy.
    Shinnar S; Pellock JM; Conry JA
    Eur J Paediatr Neurol; 2009 Jan; 13(1):3-9. PubMed ID: 18343174
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM; Yu SC; Lin CC
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness of melatonin in tardive dyskinesia.
    Castro F; Carrizo E; Prieto de Rincón D; Rincón CA; Asián T; Medina-Leendertz S; Bonilla E
    Invest Clin; 2011 Sep; 52(3):252-60. PubMed ID: 21950196
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Levetiracetam in tardive dyskinesia.
    Meco G; Fabrizio E; Epifanio A; Morgante F; Valente M; Vanacore N; Di Rosa AE; Morgante L
    Clin Neuropharmacol; 2006; 29(5):265-8. PubMed ID: 16960471
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Zonisamide for the treatment of Parkinson's disease.
    Miwa H
    Expert Rev Neurother; 2007 Sep; 7(9):1077-83. PubMed ID: 17868006
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacological treatment of tardive dyskinesia: recent developments.
    Caroff SN; Campbell EC; Carroll B
    Expert Rev Neurother; 2017 Sep; 17(9):871-881. PubMed ID: 28727483
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tardive dyskinesia (syndrome): Current concept and modern approaches to its management.
    Lerner PP; Miodownik C; Lerner V
    Psychiatry Clin Neurosci; 2015 Jun; 69(6):321-34. PubMed ID: 25556809
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Use of Zonisamide for the Treatment of Psychiatric Disorders: A Systematic Review.
    Buoli M; Grassi S; Ciappolino V; Serati M; Altamura AC
    Clin Neuropharmacol; 2017; 40(2):85-92. PubMed ID: 28195838
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial.
    Iwata Y; Irie S; Uchida H; Suzuki T; Watanabe K; Iwashita S; Mimura M
    J Neurol Sci; 2012 Apr; 315(1-2):137-40. PubMed ID: 22285275
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.